ProQR Therapeutics (PRQR) Total Current Liabilities (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Total Current Liabilities for 5 consecutive years, with $37.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 9.16% to $37.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.8 million through Dec 2025, down 9.16% year-over-year, with the annual reading at $37.8 million for FY2025, 9.16% down from the prior year.
  • Total Current Liabilities hit $37.8 million in Q4 2025 for ProQR Therapeutics, down from $41.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $41.6 million in Q4 2024 to a low of $21.4 million in Q4 2022.
  • Historically, Total Current Liabilities has averaged $33.8 million across 5 years, with a median of $36.8 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: tumbled 32.17% in 2022 and later surged 71.86% in 2023.
  • Year by year, Total Current Liabilities stood at $31.6 million in 2021, then crashed by 32.17% to $21.4 million in 2022, then soared by 71.86% to $36.8 million in 2023, then rose by 12.96% to $41.6 million in 2024, then decreased by 9.16% to $37.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for PRQR at $37.8 million in Q4 2025, $41.6 million in Q4 2024, and $36.8 million in Q4 2023.